Age-related differences in inflammatory markers in men: contribution of visceral adiposity - PubMed (original) (raw)

Age-related differences in inflammatory markers in men: contribution of visceral adiposity

Amélie Cartier et al. Metabolism. 2009 Oct.

Abstract

As visceral adipose tissue (AT) accumulation and inflammatory markers are known to increase with age, we examined whether this age-related change in regional AT distribution could contribute to the increase in the concentration of some inflammatory markers found with age. Two hundred eight healthy men aged 18.6 to 72.2 years and covering a wide range of adiposity values (body mass index, 18.5-39.3 kg/m(2)) were studied. Plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) levels were measured by enzyme-linked immunosorbent assay. Anthropometric characteristics such as height, weight, and waist girth were measured; and body mass index was calculated. Cross-sectional areas of abdominal AT were obtained at L4-L5 by computed tomography. Fasting blood samples were collected to determine a complete lipoprotein lipid profile, and a 75-g oral glucose tolerance test was performed. Overall, visceral AT accumulation was positively correlated with age (r = 0.51, P < .0001) as well as with plasma CRP (r = 0.39, P < .0001), IL-6 (r = 0.32, P < .0001), and TNF-alpha (r = 0.14, P < .05) levels. A significant positive relationship was also observed between age and CRP (r = 0.36, P < .0001), IL-6 (r = 0.39, P < .0001), or TNF-alpha (r = 0.15, P < .05) concentrations. As middle-aged men were characterized by higher CRP (1.32 [25th percentile, 0.71; 75th percentile, 2.71] vs 0.66 [0.36, 1.62] mg/L, P < .0001) and IL-6 (1.60 [1.09, 2.28] vs 1.12 [0.77, 1.60] pg/mL, P < .0001) levels as well as by a greater amount of visceral AT (P < .0001) than young men, we have individually matched 43 young men (age, 28.6 +/- 5.82 years) with 43 middle-aged men (age, 57.6 +/- 5.15 years) on the basis of their visceral AT. Matching for visceral AT eliminated the difference between middle-aged men and younger adult men in inflammatory markers. These results suggest that the age-related variation in CRP and IL-6 is largely explained by differences in visceral AT.

PubMed Disclaimer

Similar articles

• Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6.
  Park HS, Park JY, Yu R. Park HS, et al. Diabetes Res Clin Pract. 2005 Jul;69(1):29-35. doi: 10.1016/j.diabres.2004.11.007. Epub 2004 Dec 30. Diabetes Res Clin Pract. 2005. PMID: 15955385
• Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women.
  Piché ME, Lemieux S, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J. Piché ME, et al. Am J Cardiol. 2005 Jul 1;96(1):92-7. doi: 10.1016/j.amjcard.2005.02.051. Am J Cardiol. 2005. PMID: 15979442
• Postprandial variations of plasma inflammatory markers in abdominally obese men.
  Blackburn P, Després JP, Lamarche B, Tremblay A, Bergeron J, Lemieux I, Couillard C. Blackburn P, et al. Obesity (Silver Spring). 2006 Oct;14(10):1747-54. doi: 10.1038/oby.2006.201. Obesity (Silver Spring). 2006. PMID: 17062804 Clinical Trial.
• The relationship between testosterone and molecular markers of inflammation in older men.
  Maggio M, Basaria S, Ceda GP, Ble A, Ling SM, Bandinelli S, Valenti G, Ferrucci L. Maggio M, et al. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):116-9. J Endocrinol Invest. 2005. PMID: 16760639 Review.
• [Testosterone and dehydroepiandrosterone deficiency, general adiposity and visceral obesity during normal male aging].
  Medraś M, Jankowska EA. Medraś M, et al. Pol Merkur Lekarski. 2001 Aug;11(62):187-90. Pol Merkur Lekarski. 2001. PMID: 11757227 Review. Polish.

Cited by

• Saccharomyces boulardii improves clinical and paraclinical indices in overweight/obese knee osteoarthritis patients: a randomized triple-blind placebo-controlled trial.
  Dolatkhah N, Jafari A, Eslamian F, Toopchizadeh V, Saleh P, Hashemian M. Dolatkhah N, et al. Eur J Nutr. 2024 Sep;63(6):2291-2305. doi: 10.1007/s00394-024-03428-5. Epub 2024 May 18. Eur J Nutr. 2024. PMID: 38761281 Clinical Trial.
• Prevalence of dyslipidemia and its associated factors among university academic staff and students in Bangladesh.
  Ali N, Kathak RR, Fariha KA, Taher A, Islam F. Ali N, et al. BMC Cardiovasc Disord. 2023 Jul 21;23(1):366. doi: 10.1186/s12872-023-03399-1. BMC Cardiovasc Disord. 2023. PMID: 37479968 Free PMC article.
• Research progress on the mechanism of interleukin-1β on epiphyseal plate chondrocytes.
  Tong Z, Yang X, Li J. Tong Z, et al. Eur J Med Res. 2022 Dec 27;27(1):313. doi: 10.1186/s40001-022-00893-8. Eur J Med Res. 2022. PMID: 36575508 Free PMC article. Review.
• Intermuscular adipose tissue in metabolic disease.
  Goodpaster BH, Bergman BC, Brennan AM, Sparks LM. Goodpaster BH, et al. Nat Rev Endocrinol. 2023 May;19(5):285-298. doi: 10.1038/s41574-022-00784-2. Epub 2022 Dec 23. Nat Rev Endocrinol. 2023. PMID: 36564490 Review.
• The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms.
  Chen F, Chen Y, Wang Y, Ke Q, Cui L. Chen F, et al. Transl Neurodegener. 2022 Sep 11;11(1):40. doi: 10.1186/s40035-022-00316-y. Transl Neurodegener. 2022. PMID: 36089575 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal